ProJenX

ProJenX is a clinical-stage biopharmaceutical company based in Nissequogue, New York, focused on developing innovative small molecule therapeutics for the treatment of Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases. Founded in 2021, the company specializes in therapies that target motor neuron degenerative pathways. Its lead product is an oral small molecule designed to penetrate the brain and inhibit MAP4 kinases, which has demonstrated efficacy in laboratory models of ALS. This therapeutic approach aims to mitigate endoplasmic reticulum stress-mediated motor neuron loss, offering potential new options for patients suffering from these debilitating conditions.